It provides a theoretical foundation for using HBD1 as a potential antimicrobial agent against PM2.5-induced infections, facilitating the development of therapeutic strategies targeting MAPK and NF-κB pathways, and offering experimental insights into the mechanisms for mitigating airway inflammation and restoring mucosal immune functions. Here, DEFB1 is linked to infection.